Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. develops therapeutics for Alzheimer's disease and metabolic disorders as a clinical-stage biotechnology company. News about IGC Pharma commonly centers on IGC-AD1, its cannabinoid-based lead asset in the CALMA Phase 2 trial for agitation in Alzheimer's dementia, along with pipeline programs such as TGR-63, IGC-1C and IGC-M3 targeting amyloid plaques, tau pathways, neuroinflammation and related neurodegeneration biology.
Company updates also cover the use of artificial intelligence in drug discovery and clinical-trial operations, including the Agentic Harmonization Assistant platform for biomedical data harmonization. Other recurring developments include clinical-site expansion, caregiver and patient-engagement initiatives, psilocybin research authorization in Colombia, patent activity and financial reporting.
IGC Pharma (NYSE American: IGC) reported Q1 2026 results and progress on its Alzheimer’s programs. The Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer’s remains ongoing, with about 80% of the 146-patient target enrolled after March 2026 and additional U.S. trial sites activated.
IGC filed utility patent applications for its AHA AI-based data harmonization system and received a Canadian Notice of Allowance covering IGC-AD1’s composition. Q1 2026 revenue was $317,000, R&D $1.3 million, SG&A $1.2 million, and net loss attributable to shareholders $2.4 million. Debt totaled $917,000 at March 31, 2026, with an extra $585,000 debt raised afterward and access to an undrawn $12 million credit facility.
IGC Pharma (NYSE American: IGC) will present new Tau-PET biomarker research at the 2026 Global Tau Conference in Washington, D.C., May 14-15, 2026.
The study uses Shannon entropy on Tau-PET data from 931 participants to assess tau spreading patterns, cognition, and potential use in Alzheimer's monitoring and patient stratification.
IGC Pharma (NYSE American: IGC) reported participation in the caregiver podcast Autumn Is Here to raise awareness of agitation in Alzheimer's and support patient engagement in its Phase 2 CALMA trial. The company said CALMA has reached approximately 80% enrollment and is advancing toward completion.
The episode featured IGC staff discussing recognition of agitation, differences from other behavioral symptoms, and the role of caregiver education in improving clinical-trial participation.
IGC Pharma (NYSE American: IGC) added Kerwin Medical Center in Dallas as a clinical site to its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's disease on April 22, 2026. The company reported approximately 80% enrollment and says the new site brings behavioral neurology expertise to support final recruitment and data quality.
The site's Principal Investigator is Dr. Alka Khera, M.D., and Kerwin Medical Center is part of the Pinnacle Network, bringing community-based research experience intended to aid patient access and retention as the trial advances toward enrollment completion.
IGC Pharma (NYSE American: IGC) received authorization in Colombia on April 9, 2026 to synthesize, formulate, and develop psilocybin at its Bogotá R&D facility under Fondo Nacional de Estupefacientes oversight.
The capability lets IGC evaluate psilocybin for neuropsychiatric symptoms (NPS) in dementia, including depression and anxiety, while its lead program IGC-AD1 (CALMA Phase 2) is ~80% enrolled and remains the company’s near-term priority.
IGC Pharma (NYSE:IGC) announced it has reached approximately 80% enrollment in the Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer’s disease, with enrollment completion expected in mid-2026.
The randomized, double-blind, placebo-controlled study now enters its final recruitment phase, positioning the company to progress toward database lock and topline results that constitute a defined clinical catalyst.
IGC Pharma (NYSE American: IGC) said Ascendiant Capital Markets raised its equity research price target to $5.25 on April 8, 2026, citing clinical progress and expected catalysts in 2026.
The company noted its lead program, IGC-AD1, is in a Phase 2 CALMA trial for Alzheimer's-related agitation. IGC clarified analyst reports reflect analysts' views and that IGC is not responsible for analysts' content, accuracy, or timelines.
IGC Pharma (NYSE American: IGC) activated a new site for its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's dementia at Tandem Clinical Research in Metairie, Louisiana.
Principal Investigator Dr. Angela Traylor will lead the site. Enrollment is reported as over 70% complete, and the addition aims to expand geographic reach and patient access.
IGC Pharma (NYSE American:IGC) announced a 12-part national media partnership with New to The Street to expand investor awareness across institutional and retail audiences. The campaign includes long-form televised interviews, national TV commercial distribution, digital amplification to a combined 4.45 million YouTube subscribers, and outdoor billboards in Times Square and the NYC Financial District.
The company said the multi-channel effort will run as a coordinated series of placements and curated investor events designed to raise visibility while the company remains focused on disciplined clinical execution and scientific development.
IGC Pharma (NYSE:IGC)/b) filed its Form 10-KT on March 19, 2026 for the nine months ended , reflecting a fiscal year change to December year-end.
Key points: Phase 2 CALMA enrollment surpassed 70%; net loss improved by $1.8M to $4.1M; $2.7M divestiture yielded ~$1.1M non-cash profit; R&D rose 48% to $4.0M; revenue was $869k. The company highlighted U.S. patents for IGC-AD1 formulation and a microdose cannabinoid, positive preclinical in-vitro data, AI awards, and plans to complete CALMA enrollment and pursue partnerships and AI monetization in FYE 2026.